Medigene's drug Veregen® receives market authorization notification in Taiwan
(Thomson Reuters ONE) -
Medigene AG /
Medigene's drug Veregen® receives market authorization notification in Taiwan
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
Martinsried/Munich, 4 June, 2013. Medigene AG (MDG, Frankfurt, Prime Standard)
announces that its drug Veregen(®) has obtained market authorization
notification in Taiwan. Market launch of the ointment by Medigene's marketing
partner SynCore, a member of the Sinphar Pharmaceutical Group, is expected in
the second half of 2013.
Veregen(®) is already being marketed in the USA (by Fougera), in Germany,
Austria and Switzerland (by Abbott), in Spain (by Bial) as well as in Serbia (by
Pharmanova) and approved in further countries. Market approvals and the launch
in additional countries are pending in 2013. Medigene has entered into several
marketing partnerships for Veregen(®) across Europe, Asia, and America, and is
planning to continue this global licensing strategy to further leverage the
product's market potential.
About Veregen(®): Veregen(®), an ointment used in the topical treatment of
external genital warts, contains a catechin concentrate based on a defined
extract obtained from green tea leaves. Since 2010, Veregen(®) (Sinecatechins
15% ointment) has been recommended in the US Department of Health and Human
Services Center for Disease Control and Prevention's Sexually Transmitted
Diseases Treatment Guidelines as a possible option for treating genital warts.
Sinecatechins 10% & 15% ointment (Veregen(®)) was recently also included in the
European Guideline for the Management of Anogenital Warts.
About SynCore: SynCore Biotechnology Co., Ltd, a joint venture between Sinphar
Pharmaceutical Co., Ltd and the National Health Research Institute of Taiwan, is
focused on the development of new drugs. Currently, SynCore has five products
under development in different stages of clinical trial. Additionally, SynCore
has been granted the exclusive development and marketing right in Asia for a new
drug for the treatment of dry AMD (age-related macular degeneration) from
MacuCLEAR, an US-based biotech company; the drug received approval to enter into
phase II/III clinical trial in the US and Taiwan. For further information,
please visit www.syncorebio.com.
About Sinphar Pharmaceutical: Sinphar Pharmaceutical Co, Ltd (Taiwan Stock
Exchange, symbol: 1734), with subsidiaries in China and Canada, specializes in
the sales and marketing of pharmaceutical products and dietary supplements as
well as contract manufacture for several global pharma companies such as Johnson
& Johnson, Takeda, Shionogi, and Astellas. Additionally, Sinphar is one of the
major producers of paclitaxel (Phyxol(®)) in Asia. It is also involved in the
research and development of botanical new drugs. Further information can be
obtained at: www.sinphar.com.
Medigene AG (Frankfurt: MDG, Prime Standard) is a publicly listed biotech
company headquartered in Martinsried/Munich, Germany. Medigene focuses on
clinical research and development of novel drugs against cancer and autoimmune
diseases. Medigene is the first German biotech company to generate revenues from
a marketed product (Veregen(®)), which is distributed by partner companies.
Medigene also has two drug candidates undergoing clinical trials, EndoTAG(®)-1
und RhuDex(®), and is developing an innovative vaccine technology. For further
details, please visit www.medigene.com
This press release contains forward-looking statements representing the opinion
of Medigene as of the date of this release. The actual results achieved by
Medigene may differ significantly from the forward-looking statements made
herein. Medigene is not bound to update any of these forward-looking statements.
Medigene(®) and Veregen(®) are registered trademarks of Medigene AG. Polyphenon
E(® )is a trademark of Mitsui Norin Co., Ltd. These trademarks may be owned or
licensed in select locations only.
Contact
Julia Hofmann, Claudia Burmester
Investor & Public Relations
Tel.: +49 - 89 - 20 00 33 - 33 01
Email: investor(at)medigene.com
To unsubscribe from the press release distribution list, please go to
www.medigene.com/unsubscribe.
Press release as PDF:
http://hugin.info/132073/R/1706734/565039.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Medigene AG via Thomson Reuters ONE
[HUG#1706734]
Unternehmensinformation / Kurzprofil:
Datum: 04.06.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 266062
Anzahl Zeichen: 5414
contact information:
Town:
Martinsried / München
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 138 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Medigene's drug Veregen® receives market authorization notification in Taiwan"
steht unter der journalistisch-redaktionellen Verantwortung von
Medigene AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
